background: fecal microbiota transplant (fmt) is employed to replace the ‘unhealthy’ microbiota of the patient with the ‘healthy’ microbiota of a pre-screened healthy donor. given the growing importance of gut microbiota dysbiosis in the pathogenesis of intestinal or extraintestinal diseases; it is conceivable that fmt becomes integrated in the routine clinical practice. our objective was to as...

fecal microbiota transplant (fmt) research trials are growing in diverse intestinal and extraintestinal conditions that are thought to be either caused or correlated with gut microbiota dysbiosis. although, the mechanism by which the microbiota results in disease initiation or progression is not fully understood, it is speculated that restoring the symbiosis by fmt could have therapeutic benefits.

We report the use of fecal microbiota transplantation in a single heart-kidney transplant recipient with recurrent Clostridium difficile, vancomycin-resistant Enterococcus (VRE) fecal dominance, and recurrent VRE infections. Fecal microbiota transplantation resulted in the reconstruction of a diverse microbiota with (1) reduced relative abundance of C difficile and VRE and (2) positive clinical...

BACKGROUND AND AIMS Fecal microbiota transplantation is used with success in persistent (more than two episodes) Clostridium Difficile Infection; it has also gained importance and started to be used in inflammatory bowel disease. There are theoretical arguments that justify its use in ulcerative colitis or Crohn's disease. Based on our clinical cases we tried to evaluate the indications of feca...

The prevalence of recurrent or refractory Clostridium difficile infection has been steadily increasing since 2000. Consequently, alternative treatments to the standard antibiotic therapies are now being considered. One alternative treatment is fecal microbiota transplant. Although fecal microbiota transplant is relatively new--and not appealing to most people--it has been around for many years ...

Fecal microbiota transplantation is a compelling treatment for recurrent Clostridium difficile infections, with potential applications against other diseases associated with changes in gut microbiota. But variability in fecal bacterial communities-believed to be the therapeutic agent-can complicate or undermine treatment efficacy. To understand the effects of transplant preparation methods on l...

Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent C...

conclusions with regard to improving the understanding of the differences in the biodiversity of the fecal microbiota between rd infants and h infants, the findings of this study can provide a possible basis to reveal the relationship between rd and intestinal microbiota. objectives this study aimed to reveal the changes in the biodiversity of the fecal microbiota of infants with rd. patients a...